Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 60%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is well-positioned in the oncology biopharmaceutical market with its top-prescribed drug, BRUKINSA, and a strong financial foundation. This, along with their pipeline of promising candidates, makes the company a leader in CLL treatment and also positions them for potential growth in solid tumor treatments. The company's focus on diversity and ethical standards also adds to its long-term value creation potential.

Bears say

BeOne Medicines is a holding company operating in the pharmaceutical products segment, generating the majority of its revenue from the sale of its oncology-focused biopharmaceutical products, including BRUKINSA, sonrotoclax, and BTK-CDAC. However, their projected revenue growth of 32% in 2025 is insufficient to offset the combined 10-year royalty revenue of only ~$1.3B for Imdelltra, and they face challenges in comparison with other drugs in development and defending their market exclusivity. Furthermore, they face material sustainability issues and potential geopolitical risks, and their high cash burn on the pipeline may not lead to marketable drugs, which could result in substantial downside if Brukinsa, their key revenue driver, faces any pressure.

BeiGene Ltd (ONC) has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 60% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 10 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $385.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $385.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.